Work

CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123

Year: 2024

Type: article

Source: Leukemia Research

DOI: 10.1016/j.leukres.2024.107479

Authors: Xiaoyi Hu, Asiri Ediriwickrema, Atif Saleem, Brent Tan, Naveen Pemmaraju, Gabriel N. Mannis

Institutions: Stanford Medicine, Stanford Cancer Institute, Stanford University, The University of Texas MD Anderson Cancer Center

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4392648496

FWCI: 0.681

Cites: 20

Cited by: 4

Related to: 10